{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:39Z","timestamp":1791169419993,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,4,18]],"date-time":"2004-04-18T00:00:00Z","timestamp":1082246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1038\/ng1343","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T21:46:19Z","timestamp":1082583979000},"page":"453-461","source":"Crossref","is-referenced-by-count":338,"title":["Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia"],"prefix":"10.1038","volume":"36","author":[{"given":"Yiguo","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Buchdunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Warmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,4,18]]},"reference":[{"key":"BFng1343_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers, C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330\u20131340 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFng1343_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B.J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFng1343_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645\u2013652 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFng1343_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL1 gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"BFng1343_CR5","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472\u20133475 (2002).","journal-title":"Blood"},{"key":"BFng1343_CR6","doi-asserted-by":"publisher","first-page":"10700","DOI":"10.1073\/pnas.162140299","volume":"99","author":"S Roumiantsev","year":"2002","unstructured":"Roumiantsev, S. et al. Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 99, 10700\u201310705 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFng1343_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N.P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002).","journal-title":"Cancer Cell"},{"key":"BFng1343_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattler","year":"2003","unstructured":"Sattler, M. & Griffin, J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol. 40, 4\u201310 (2003).","journal-title":"Semin. Hematol."},{"key":"BFng1343_CR9","first-page":"3589","volume":"56","author":"S Danhauser-Riedl","year":"1996","unstructured":"Danhauser-Riedl, S., Warmuth, M., Druker, B.J., Emmerich, B. & Hallek, M. Activation of Src kinases p53\/56Lyn and p59Hck by p210Bcr\/Abl in myeloid cells. Cancer Res. 56, 3589\u20133596 (1996).","journal-title":"Cancer Res."},{"key":"BFng1343_CR10","doi-asserted-by":"publisher","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","volume":"272","author":"M Warmuth","year":"1997","unstructured":"Warmuth, M. et al. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. 272, 33260\u201333270 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFng1343_CR11","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman, A. et al. The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 21, 5766\u20135774 (2002).","journal-title":"EMBO J."},{"key":"BFng1343_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.leu.2402778","volume":"17","author":"M Stanglmaier","year":"2003","unstructured":"Stanglmaier, M., Warmuth, M., Kleinlein, I., Reis, S. & Hallek, M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 17, 283\u2013289 (2003).","journal-title":"Leukemia"},{"key":"BFng1343_CR13","doi-asserted-by":"publisher","first-page":"18581","DOI":"10.1074\/jbc.C000126200","volume":"275","author":"JM Lionberger","year":"2000","unstructured":"Lionberger, J.M., Wilson, M.B. & Smithgall, T.E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. 275, 18581\u201318585 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFng1343_CR14","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1038\/sj.onc.1206008","volume":"21","author":"MB Wilson","year":"2002","unstructured":"Wilson, M.B., Schreiner, S.J., Choi, H.J., Kamens, J. & Smithgall, T.E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21, 8075\u20138088 (2002).","journal-title":"Oncogene"},{"key":"BFng1343_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood-2002-01-0288","volume":"101","author":"M Warmuth","year":"2003","unstructured":"Warmuth, M. et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101, 664\u2013672 (2003).","journal-title":"Blood"},{"key":"BFng1343_CR16","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1038\/sj.onc.1206091","volume":"21","author":"RA Van Etten","year":"2002","unstructured":"Van Etten, R.A. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 21, 8643\u20138651 (2002).","journal-title":"Oncogene"},{"key":"BFng1343_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li, S., Ilaria, R.L., Million, R.P., Daley, G.Q. & Van Etten, R.A. The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399\u20131412 (1999).","journal-title":"J. Exp. Med."},{"key":"BFng1343_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.V97.1.4","volume":"97","author":"S Roumiantsev","year":"2001","unstructured":"Roumiantsev, S., de Aos, I., Varticovski, L., Ilaria, R.L. & Van Etten, R.A. The Src homology 2 domain of Bcr\/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97, 4\u201313 (2001).","journal-title":"Blood"},{"key":"BFng1343_CR19","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood.V97.5.1442","volume":"97","author":"S Li","year":"2001","unstructured":"Li, S. et al. Interleukin-3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR\/ABL . Blood 97, 1442\u20131450 (2001).","journal-title":"Blood"},{"key":"BFng1343_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","volume":"7","author":"VW Chan","year":"1997","unstructured":"Chan, V.W., Meng, F., Soriano, P., DeFranco, A.L. & Lowell, C.A. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7, 69\u201381 (1997).","journal-title":"Immunity"},{"key":"BFng1343_CR21","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","volume":"84","author":"J McLaughlin","year":"1987","unstructured":"McLaughlin, J., Chianese, E. & Witte, O.N. In vitro transformation of immature hematopoietic cells by the P210 bcr\/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84, 6558\u20136562 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFng1343_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","volume":"12","author":"KM Smith","year":"2003","unstructured":"Smith, K.M., Yacobi, R. & Van Etten, R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell 12, 27\u201337 (2003).","journal-title":"Mol. Cell"},{"key":"BFng1343_CR23","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood.V98.9.2808","volume":"98","author":"NC Wolff","year":"2001","unstructured":"Wolff, N.C. & Ilaria, R.L. Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98, 2808\u20132816 (2001).","journal-title":"Blood"},{"key":"BFng1343_CR24","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","volume":"100","author":"RR Hoover","year":"2002","unstructured":"Hoover, R.R., Mahon, F.-X., Melo, J.V. & Daley, G.Q. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood 100, 1068\u20131071 (2002).","journal-title":"Blood"},{"key":"BFng1343_CR25","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman, A., Rushen, L., Morrione, A., Slupianek, A. & Skorski, T. Phosphatidylinositol 3-kinase inhibitors enhance the anti-leukemic effect of STI571. Oncogene 21, 5868\u20135876 (2002).","journal-title":"Oncogene"},{"key":"BFng1343_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/0092-8674(95)90277-5","volume":"82","author":"A Goga","year":"1995","unstructured":"Goga, A., McLaughlin, J., Afar, D.E., Saffran, D.C. & Witte, O.N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82, 981\u2013988 (1995).","journal-title":"Cell"},{"key":"BFng1343_CR27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V96.2.664","volume":"96","author":"RP Million","year":"2000","unstructured":"Million, R.P. & Van Etten, R.A. The Grb2 binding site is required for induction of chronic myeloid leukemia-like disease in mice by the Bcr\/Abl tyrosine kinase. Blood 96, 664\u2013670 (2000).","journal-title":"Blood"},{"key":"BFng1343_CR28","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1084\/jem.185.9.1661","volume":"185","author":"F Meng","year":"1997","unstructured":"Meng, F. & Lowell, C.A. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J. Exp. Med. 185, 1661\u20131670 (1997).","journal-title":"J. Exp. Med."},{"key":"BFng1343_CR29","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","volume":"99","author":"Y He","year":"2002","unstructured":"He, Y. et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr\/abl. Blood 99, 2957\u20132968 (2002).","journal-title":"Blood"},{"key":"BFng1343_CR30","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1073\/pnas.102583199","volume":"99","author":"AB Dash","year":"2002","unstructured":"Dash, A.B. et al. A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOX49 . Proc. Natl. Acad. Sci. USA 99, 7622\u20137627 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFng1343_CR31","doi-asserted-by":"publisher","first-page":"8236","DOI":"10.1038\/sj.onc.1205095","volume":"20","author":"GM Cuenco","year":"2001","unstructured":"Cuenco, G.M. & Ren, R. Cooperation of BCR-ABL and AML1\/MDS1\/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20, 8236\u20138248 (2001).","journal-title":"Oncogene"},{"key":"BFng1343_CR32","first-page":"7149","volume":"62","author":"P La Rosee","year":"2002","unstructured":"La Rosee, P., Corbin, A.S., Stoffregen, E.P., Deininger, M.W. & Druker, B.J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62, 7149\u20137153 (2002).","journal-title":"Cancer Res."},{"key":"BFng1343_CR33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato, N.J. et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690\u2013698 (2003).","journal-title":"Blood"},{"key":"BFng1343_CR34","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1182\/blood.V96.6.2277","volume":"96","author":"V Sexl","year":"2000","unstructured":"Sexl, V. et al. Stat5a\/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr\/abl-induced transformation are independent of STAT5. Blood 96, 2277\u20132283 (2000).","journal-title":"Blood"},{"key":"BFng1343_CR35","doi-asserted-by":"crossref","first-page":"15381","DOI":"10.1016\/S0021-9258(17)36617-6","volume":"269","author":"T Tauchi","year":"1994","unstructured":"Tauchi, T. et al. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J. Biol. Chem. 269, 15381\u201315387 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFng1343_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nm0102-61","volume":"8","author":"I Daigle","year":"2002","unstructured":"Daigle, I., Yousefi, S., Colonna, M., Green, D.R. & Simon, H.U. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat. Med. 8, 61\u201367 (2002).","journal-title":"Nat. Med."},{"key":"BFng1343_CR37","first-page":"1126","volume":"26","author":"W Yang","year":"1998","unstructured":"Yang, W. et al. SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased Lyn kinase activity. Exp. Hematol. 26, 1126\u20131132 (1998).","journal-title":"Exp. Hematol."},{"key":"BFng1343_CR38","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.1093\/emboj\/20.23.6793","volume":"20","author":"S Li","year":"2001","unstructured":"Li, S., Couvillon, A.D., Brasher, B.B. & Van Etten, R.A. Tyrosine phosphorylation of Grb2 by Bcr\/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 20, 6793\u20136804 (2001).","journal-title":"EMBO J."},{"key":"BFng1343_CR39","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","volume":"92","author":"WS Pear","year":"1998","unstructured":"Pear, W.S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow. Blood 92, 3780\u20133792 (1998).","journal-title":"Blood"},{"key":"BFng1343_CR40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V83.1.43.43","volume":"83","author":"MH Finer","year":"1994","unstructured":"Finer, M.H., Dull, T.J., Qin, L., Farson, D. & Roberts, M. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83, 43\u201350 (1994).","journal-title":"Blood"}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ng1343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ng1343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ng1343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:06:07Z","timestamp":1684447567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ng1343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,18]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["BFng1343"],"URL":"https:\/\/doi.org\/10.1038\/ng1343","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,18]]}}}